B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

EIF2AK2

MOLECULAR TARGET

eukaryotic translation initiation factor 2 alpha kinase 2

UniProt: P19525NCBI Gene: 561025 compounds

EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EIF2AK2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1erlotinib5.55256
2alvocidib4.5291
3bi 25364.0154
4midostaurin3.8546
5pazopanib3.6939
6pelitinib3.5032
76bio3.5032
8fedratinib3.4029
9sp 6001253.2224
10dorsomorphin3.1422
11dovitinib3.0921
12jnj 77066213.0921
13lestaurtinib3.0420
14r 4062.8316
15su 95162.8316
16kw 24492.6413
17gsk 6906932.6413
18ast 4872.5612
19raf 2652.4811
20su 0148132.208
21anilinopyrimidine11.795
22quinoxaline11.795
23Axitinib0.691
24Crizotinib0.691
25sp6001250.691

About EIF2AK2 as a Drug Target

EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented EIF2AK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EIF2AK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.